Aerovate Therapeutics Inc (AVTE)
$2.3
Live
Performance
- $2.29$2.37$2.30
0.41%
Downside
Day's Volatility :3.35%
Upside
2.95%
- $1.25$32.42$2.30
45.65%
Downside
52 Weeks Volatility :96.14%
Upside
92.9%
Returns
| Period | Aerovate Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 28.8% | 3.6% | 0.0% |
6 Months | -89.31% | 10.2% | 0.0% |
1 Year | -78.51% | 19.6% | 0.0% |
3 Years | -81.78% | 16.8% | -23.0% |
Highlights
Market Capitalization | 67.0M |
Book Value | $3.27 |
Earnings Per Share (EPS) | -3.13 |
Wall Street Target Price | 2.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -44.04% |
Return On Equity TTM | -74.42% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -94.1M |
Diluted Eps TTM | -3.13 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.78 |
EPS Estimate Next Year | -1.0 |
EPS Estimate Current Quarter | -0.82 |
EPS Estimate Next Quarter | -0.66 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1.3%
Technicals Summary
Sell
Neutral
Buy
Aerovate Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aerovate Therapeutics Inc | 25.4% | -89.31% | -78.51% | -81.78% | -84.24% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aerovate Therapeutics Inc | 0.88 | NA | NA | -2.78 | -0.74 | -0.44 | NA | 3.27 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aerovate Therapeutics Inc | Buy | $67.0M | -84.24% | 0.88 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Aerovate Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 161.6%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 126.6%
Institutional Holdings
RA Capital Management, LLC
31.84%Sofinnova Ventures
13.02%TCG Crossover Management, LLC
7.76%Deerfield Management Co
4.89%Vanguard Group Inc
3.83%BlackRock Inc
3.41%
Company Information
aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Organization | Aerovate Therapeutics Inc |
Employees | 51 |
CEO | Mr. Timothy P. Noyes M.B.A. |
Industry | Healthcare |
